How can a blood transfusion affect hepatitis B screening results?

Effect of Blood Transfusion on Hepatitis B Screening

Bolded recommendation: A recent blood transfusion can transiently alter hepatitis B serology (anti-HBs and anti-HBc) without indicating true infection, but it should not cause a false-positive HBsAg; if screening is needed soon after transfusion, use the full triple panel (HBsAg, anti-HBs, total/IgM anti-HBc) and, when results are discordant or unexpected, repeat testing after 8–12 weeks and consider HBV DNA/NAT. 1, 2

• What can change right after transfusion

  • Passive antibodies from donor plasma can appear in the recipient:
    • Anti-HBs may become temporarily positive, mimicking immunity.
    • Total anti-HBc (and rarely IgM anti-HBc) may appear transiently, mimicking recent/remote infection. This is a known cause of false interpretation post-transfusion. 1, 3
  • HBsAg
    • Should not be positive from passive transfer because donor blood is screened; a positive HBsAg post-transfusion suggests true infection and warrants evaluation. Residual transmission risk exists but is very low in modern blood systems. 1, 2

• Clinical algorithm (prioritizing morbidity, mortality, QoL)

  1. If urgent screening is needed within 8–12 weeks of transfusion:
     • Order HBsAg, total anti-HBc, IgM anti-HBc, and anti-HBs together. 1
     • If HBsAg positive: evaluate as infection (confirm, check ALT, HBV DNA), as this impacts outcomes via chronic HBV risk. 1
     • If HBsAg negative but anti-HBc and/or anti-HBs positive: consider passive transfer; document transfusion timing; obtain HBV DNA (NAT) if results will change management (e.g., immunosuppression planned). 2, 3
  2. If screening is not urgent:
     • Defer serology 8–12 weeks post-transfusion to avoid passive antibody confounding; repeat full panel then. This timing reduces misclassification that could affect prophylaxis/treatment decisions. 1
  3. High-stakes situations (e.g., imminent immunosuppression, pregnancy, transplant):
     • Do triple panel plus HBV DNA now; repeat serology at 8–12 weeks to confirm true status and guide antiviral prophylaxis, preventing HBV reactivation and its morbidity/mortality. 1, 2

• Key nuances and pitfalls

  • Very low but nonzero HBV transmission risk remains due to window-period or occult infection despite screening; unexplained HBsAg positivity or seroconversion after transfusion must be taken seriously. 2, 3
  • Isolated anti-HBc after transfusion is common and often passive; do not label as chronic infection without confirmatory DNA and follow-up serology. Avoid unnecessary lifelong “HBV carrier” designation. 3
  • Anti-HBs positivity immediately post-transfusion may not reflect vaccine-derived immunity of the recipient; verify immunity status later to ensure appropriate vaccination decisions that impact long-term HBV-related outcomes. 1

• Bottom line for interpretation timing

  • Within weeks of transfusion: expect possible transient anti-HBs/anti-HBc; HBsAg should remain reliable.
  • Best confirmation: repeat full serology at 8–12 weeks and use HBV DNA if results will alter near-term care. 1